Literature DB >> 22826034

Drug repurposing: far beyond new targets for old drugs.

T I Oprea1, J Mestres.   

Abstract

Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug-target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.

Mesh:

Substances:

Year:  2012        PMID: 22826034      PMCID: PMC3475856          DOI: 10.1208/s12248-012-9390-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  34 in total

1.  Surviving the blockbuster syndrome.

Authors:  Robert F Service
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

2.  Wrong questions, wrong answers? Are we getting the drugs we need?

Authors:  W L Lipworth; I H Kerridge; R O Day
Journal:  Clin Pharmacol Ther       Date:  2012-03       Impact factor: 6.875

3.  Drug discovery in jeopardy.

Authors:  Pedro Cuatrecasas
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

4.  Big interest in heavy drugs.

Authors:  Katharine Sanderson
Journal:  Nature       Date:  2009-03-19       Impact factor: 49.962

5.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

6.  The molecular basis for coxib inhibition of p38alpha MAP kinase.

Authors:  Gilberto M Sperandio da Silva; Lidia M Lima; Carlos A M Fraga; Carlos M R Sant'Anna; Eliezer J Barreiro
Journal:  Bioorg Med Chem Lett       Date:  2005-08-01       Impact factor: 2.823

7.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

8.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Authors:  T Kawamori; C V Rao; K Seibert; B S Reddy
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

9.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.

Authors:  Alexander Weber; Angela Casini; Andreas Heine; Daniel Kuhn; Claudiu T Supuran; Andrea Scozzafava; Gerhard Klebe
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

10.  Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.

Authors:  Daichi Shigemizu; Zhenjun Hu; Jui-Hung Hung; Chia-Ling Huang; Yajie Wang; Charles DeLisi
Journal:  PLoS Comput Biol       Date:  2012-02-09       Impact factor: 4.475

View more
  73 in total

1.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

Review 2.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 3.  Drug repurposing from the perspective of pharmaceutical companies.

Authors:  Y Cha; T Erez; I J Reynolds; D Kumar; J Ross; G Koytiger; R Kusko; B Zeskind; S Risso; E Kagan; S Papapetropoulos; I Grossman; D Laifenfeld
Journal:  Br J Pharmacol       Date:  2017-05-18       Impact factor: 8.739

4.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

5.  High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method.

Authors:  Morgan A Wambaugh; Jessica C S Brown
Journal:  J Vis Exp       Date:  2018-05-21       Impact factor: 1.355

Review 6.  Shifting from the single to the multitarget paradigm in drug discovery.

Authors:  José L Medina-Franco; Marc A Giulianotti; Gregory S Welmaker; Richard A Houghten
Journal:  Drug Discov Today       Date:  2013-01-20       Impact factor: 7.851

7.  MOLIERE: Automatic Biomedical Hypothesis Generation System.

Authors:  Justin Sybrandt; Michael Shtutman; Ilya Safro
Journal:  KDD       Date:  2017-08

8.  Spore Germination as a Target for Antifungal Therapeutics.

Authors:  Sébastien C Ortiz; Mingwei Huang; Christina M Hull
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

Review 9.  Polypharmacology: drug discovery for the future.

Authors:  A Srinivas Reddy; Shuxing Zhang
Journal:  Expert Rev Clin Pharmacol       Date:  2013-01       Impact factor: 5.045

10.  High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects.

Authors:  Sunil Sahdeo; Alexey Tomilov; Kelly Komachi; Christine Iwahashi; Sandipan Datta; Owen Hughes; Paul Hagerman; Gino Cortopassi
Journal:  Mitochondrion       Date:  2014-07-14       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.